Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate
Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate
再鼎醫藥2024年第二季度每股美國通用會計準則虧損$(0.82)，未達到$(0.70)的預期，銷售額爲10050.4萬元，超出了9313.6萬元的預期。
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.82) per ADS which missed the analyst consensus estimate of $(0.70) by 17.14 percent. This is a 34.4 percent increase over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $100.504 million which beat the analyst consensus estimate of $93.136 million by 7.91 percent. This is a 45.95 percent increase over sales of $68.864 million the same period last year.
再鼎醫藥（納斯達克：ZLAB）報告每個美國存托股份ADS的季度虧損爲0.82美元，比分析師共識估計的0.70美元低了17.14％。這比去年同期每股虧損1.25美元增長了34.4％。該公司報告的季度銷售額爲1.00504億美元，比分析師共識估計的9313.6萬美元高7.91％。這是銷售額同比增長45.95％的結果。